These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16550474)

  • 1. Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.
    Mohutsky MA; Chien JY; Ring BJ; Wrighton SA
    Pharm Res; 2006 Apr; 23(4):654-62. PubMed ID: 16550474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.
    Soars MG; Burchell B; Riley RJ
    J Pharmacol Exp Ther; 2002 Apr; 301(1):382-90. PubMed ID: 11907196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma.
    Skaggs SM; Foti RS; Fisher MB
    J Pharmacol Toxicol Methods; 2006; 53(3):284-90. PubMed ID: 16300971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties.
    Austin RP; Barton P; Cockroft SL; Wenlock MC; Riley RJ
    Drug Metab Dispos; 2002 Dec; 30(12):1497-503. PubMed ID: 12433825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.
    Obach RS
    Drug Metab Dispos; 1999 Nov; 27(11):1350-9. PubMed ID: 10534321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
    Cubitt HE; Houston JB; Galetin A
    Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
    Miners JO; Knights KM; Houston JB; Mackenzie PI
    Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model.
    Lundquist P; Lööf J; Fagerholm U; Sjögren I; Johansson J; Briem S; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):459-68. PubMed ID: 24396143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes.
    Poulin P; Haddad S
    J Pharm Sci; 2011 Oct; 100(10):4501-17. PubMed ID: 21574165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance.
    Deshmukh SV; Harsch A
    J Pharmacol Toxicol Methods; 2011; 63(1):35-9. PubMed ID: 20433934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative prediction of glucuronidation in humans using the in vitro- in vivo extrapolation approach.
    Wu B; Dong D; Hu M; Zhang S
    Curr Top Med Chem; 2013; 13(11):1343-52. PubMed ID: 23675940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prediction of human clearance from hepatic microsomal metabolism data.
    Obach RS
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):36-44. PubMed ID: 11727321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
    Obach RS
    Drug Metab Dispos; 1997 Dec; 25(12):1359-69. PubMed ID: 9394025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
    Naritomi Y; Nakamori F; Furukawa T; Tabata K
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative assessment of empirical and physiological approaches on predicting human clearances.
    Tamaki S; Komura H; Kogayu M; Yamada S
    J Pharm Sci; 2011 Mar; 100(3):1147-55. PubMed ID: 20830811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.
    Ye M; Nagar S; Korzekwa K
    Biopharm Drug Dispos; 2016 Apr; 37(3):123-41. PubMed ID: 26531057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay.
    Berezhkovskiy LM; Khojasteh SC; Halladay JS; Hop CE
    J Pharm Sci; 2009 Jun; 98(6):1922-7. PubMed ID: 18837013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of intrinsic clearance for prediction of human hepatic clearance.
    Chao P; Uss AS; Cheng KC
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):189-98. PubMed ID: 20073997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties.
    Bowman CM; Benet LZ
    Pharm Res; 2019 May; 36(8):113. PubMed ID: 31152241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.
    Ito K; Houston JB
    Pharm Res; 2004 May; 21(5):785-92. PubMed ID: 15180335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.